9621 Agnes Crossing, Lake Suzanneview, New Mexico Island 84604-9295.
EFE Chinese biopharmaceutical company Sinovac Biotech, the manufacturer of one of the most widely administered vaccines against covid-19 in several Latin American countries, began construction of its first
Chinese biopharmaceutical company Sinovac Biotech, the manufacturer of one of the most widely administered vaccines against covid-19 in several Latin American countries, began construction of its first packaging facility in the region this Thursday in Santiago de Chile.
The facility, with an annual filling and packaging capacity of 50 million doses, will be ready before 2023. A massive opening ceremony will require an investment of $100 million, according to company sources.
«Sinovac will devote himself to investment and scientific research in Chile. Anything to improve manufacturing that gives more people access to vaccines in South America. This was stated in a virtual intervention by Weidong Yin, the director of the Chinese company.
The facility, which has an area of 22,000 meters, will package vials against covid-19, hepatitis A and influenza. That’s what biochemist Virginia Garretón, vice president of corporate affairs at Sinovac Biotech Chile, told Efe.
“The vaccines are made in China with the original inactivated virus, sent to filling facilities; and here they are packaged under extremely safe conditions for distribution,” he explained.
Chilean Minister of Science, immunologist Flavio Salazar, told Efe that the installation of this plant aims to “make Chile a pole for the distribution of vaccines at the Latin American level.”
“Centralization in vaccine production is causing great inequality in their distribution in emergencies like covid-19,” he said.
The idea is to move towards “the creation of connected systems to express regional responses and promote Latin American integration.”
“We’re already working on that with Argentina, Mexico and Brazil,” he said.
Similarly, this week Sinovac announced that it will allocate an additional $100 million for the construction of a vaccine production facility in Bogotá. This includes a 10-year project that will begin in 2023.
CoronaVac serum, Sinovac’s vaccine against covid-19, is in the majority in Chile. Also available in Uruguay, Dominican Republic, Colombia, Ecuador and Brazil.
Until the World Health Organization (WHO) approved it for emergency use in June 2021, the only reliable studies on its effectiveness and efficiency were those conducted by the University of Chile and the Chilean government.
The research determined that CoronaVac has an effectiveness of 65.3% in stopping infections, compared to 95% of Pfizer / BioNTech and 80% of AstraZeneca.
Weidong Yin thanked Chilean scientists for their work on the clinical application of the vaccine and noted that the collaboration with Chinese researchers was successful.
“They made it possible for CoronaVac to have a greater global impact. “The results of his research are of great help to WHO and to formulating strategies in many countries,” said the CEO of the company, headquartered in Beijing.
Thanks to the mass distribution of CoronaVac, Chile has been at the forefront of immunization in the region, with more than 93% of the population with the full program and more than 80% with a booster dose.
Source: El Nacional
Alice Smith is a seasoned journalist and writer for Div Bracket. She has a keen sense of what’s important and is always on top of the latest trends. Alice provides in-depth coverage of the most talked-about news stories, delivering insightful and thought-provoking articles that keep her readers informed and engaged.
